TORONTO, Ontario — December 18, 2025 — Leads & Copy — Conavi Medical Corp. (TSXV: CNVI) announced the pricing and terms of its previously announced public offering of common shares and pre-funded common share purchase warrants.
The offering will be conducted on a commercially reasonable efforts agency basis for the issuance of a minimum of 33,333,333 securities and a maximum of 44,444,444 securities at a price of $0.45 per common share or $0.44999 per pre-funded warrant, for gross proceeds of between $15,000,000 and $20,000,000.
Each pre-funded warrant entitles the holder to acquire one common share at an exercise price of $0.00001 per common share. The pre-funded warrants will not expire and may be exercised on a “net” or “cashless” basis.
Conavi intends to use the net proceeds from the offering to obtain US FDA 510(k) clearance of the next generation Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the United States. The company also intends to use the net proceeds for working capital and other general corporate purposes.
The offering is expected to be completed pursuant to the terms and conditions of an agency agreement entered into between the company and Bloom Burton Securities Inc.
Conavi is expecting to file today, on December 18, 2025, a final short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia, and Ontario. There will not be any sale of securities until a receipt for the final prospectus has been issued.
The offering may be completed in one or more tranches and is expected to close initially on or about December 23, 2025, or such other date as may be mutually agreed to by the company and the agent. The offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange.
Conavi will pay to the agent a cash fee equal to 6.5% of the gross proceeds raised under the offering and grant the agent compensation options equal to 6.5% of the aggregate number of securities issued under the offering. The agent will receive a reduced cash commission of 3.25% and no compensation options in respect of securities sold to certain purchasers on a president’s list to be agreed to between the company and the agent. Each compensation option entitles the holder to buy one common share at the same price per common share as under the offering. The compensation options shall be exercisable until that date which is 24 months following the closing date.
In addition, the securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons except pursuant to an exemption from the registration requirements under the U.S. Securities Act and applicable U.S. state securities laws.
The final prospectus (when filed) will be accessible on SEDAR+ at www.sedarplus.ca. Alternatively, an electronic or paper copy of the final prospectus (when filed), as well as any amendment to such documents, may be obtained without charge from the agent by email at ECM@bloomburton.com, by telephone at 416-640-7585 or by providing the contact with an email address or address, as applicable. Prospective investors should read the final prospectus (when filed) before making an investment decision.
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid System combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device. The first-generation Novasight Hybrid System has 510(k) regulatory clearance in the U.S., Canada, China, and Japan.
Christina Cameron IR@conavi.com
Source: Conavi Medical
